A study on long term outcomes following variceal eradication in patients with extrahepatic portal venous obstruction (EHPVO) was clearly needed. In this issue of the Journal, Thomas et al. present the results of long-term follow up of a cohort of patients treated with endoscopic variceal sclerotherapy (EST). Of the 223 patients treated between 1985 and 1994, they had follow up data available for 198 patients. On a retrospective analysis of these data, 34 (17.2%) patients had rebleeding after initial variceal eradication, 39 (19.7%) had reappearance of esophageal varices and 19 (9.5%) had de novo appearance of fundal varices. The mean duration from the time of eradication of varices to rebleeding was 5.4 (range 1 to 16) years. Based on these results, the authors suggest that endoscopic variceal eradication is an effective treatment modality for bleeding esophageal varices in patients with EHPVO.
This study, though retrospective, is quite thorough. 1 It clarifies several questions, while throwing up some new ones. First, the authors base their premise on a cohort of patients in whom they had achieved successful initial hemostasis and long term variceal eradication. A large majority (87%) of their patients presented with active variceal bleeding. However, we remain unsure of the outcome in patients in whom initial EST failed to achieve hemostasis. In 10%-15% of patients, endoscopic treatment may not achieve initial control of bleeding. 2, 3 This subset of patients is important since their exclusion may mislead us into believing that EST is successful in all patients with variceal bleeding due to EHPVO. Secondly, 12 patients were lost to follow up from the initial cohort of 223 patients; did these patients die or undergo some other form of treatment elsewhere? No doubt the long term results are important, but without these initial data, establishing the overall efficacy of EST in this group of patients would be incomplete.
In the broader clinical perspective, the treatment options available for patients with EHPVO must include surgery. Evidence in the Western literature indicates that if shunt surgery has a role in treatment of portal hypertension, it is in patients with non-cirrhotic portal hypertension, and especially those with EHPVO. 4, 5 From India too, excellent long term results of proximal lieno-renal shunt (PLRS) have been reported in such patients. Of 160 children who underwent PLRS with splenectomy at our institution, the overall mortality was 1.9% (elective: 1/140 [0.7%]; emergency 2/20 [10%]), rebleeding rate was 11% and actuarial survival at 15 years by life-table analysis was 95%. 6, 7 None of these patients developed encephalopathy. The procedure cured hypersplenism in all the patients who had this. Only one patient developed meningococcal meningitis, which recovered following treatment. Similarly, a study from Chandigarh that included 104 patients with non-cirrhotic portal hypertension who had undergone side-to-side lieno-renal shunt showed a shunt patency rate of 87%, a rebleeding rate of 10%, and no occurrence of encephalopathy after a mean follow up of 54 months. 8 Thus, surgery is a one-time treatment procedure with durable, long term efficacy in preventing variceal rebleeding.
Long term studies (15-40 years) from the West have repeatedly shown that shunt surgery with or without splenectomy (proximal lieno-renal, side-to-side splenorenal, distal splenorenal or mesocaval) for EHPVO in children and adults, is associated with shunt patency rates between 90% and 95%, rebleeding rates of 5%-10%, no encephalopathy and 15-year actual survival rates of 95%. 5, [9] [10] [11] These studies have found portosystemic shunts to be consistently effective for bleeding esophagogastric varices due to EHPVO. 12 Goyal et al. reported a rebleeding rate of 10% and a 95% overall survival among 22 patients with non-cirrhotic portal hypertension undergoing esophagogastric devascularization who were followed for a mean duration of 4 years. 13 Orozco et al. from Mexico reported similar results in a selected group of patients with EHPVO (n=38) undergoing the one-stage or two-stage Sugiura procedure. 14 The surgical options do not end here. A new type of shunt, the mesenterico-left portal vein bypass (Rex shunt), has been described recently, and is a new paradigm in surgical treatment. 15 This procedure decompresses the portal venous system while simultaneously restoring portal blood flow to the liver. Follow up results ranging between 1 and 7 years are available. In the largest study reported till date, 34 patients underwent this procedure with a success rate of 91%, good shunt patency rate, and rebleeding rate of 8% with amelioration of hypersplenism in most patients. 15 Any therapeutic modality for management of variceal bleeding due to EHPVO has to be assessed against this long-term surgical experience. In addition, one must keep in mind that patients with EHPVO in India are young, have normal liver function, tolerate episodes of variceal bleeding well, and are generally expected to have a near normal life expectancy if bleeding does not recur.
Access to tertiary healthcare and blood bank facilities is still limited in large parts of India. It is in this context that the study published in this issue of the Journal assumes importance. This study has for the first time provided data based on a long duration of follow up after variceal obliteration of a large cohort of patients with EHPVO. 1 It shows efficacy of EST by showing a high long term survival rate (195/198) and acceptable rebleeding rate (~17%). However, one has to also consider the potential for such therapy to adversely affect the natural course of the underlying disease, cause long term complications and alter the quality of life (QOL) of patients with EHPVO who are in the prime of their life.
It has been hypothesized that obliteration of varices by endoscopic means may induce the formation of new gastric varices, ectopic varices and severe portal hypertensive gastropathy, and may lead to worsening of portal biliopathy. 3, 16, 17 This is thought to be due to the persistence of portal pressure. In the study under review, 10% (n=19) of patients developed new gastric varices, of whom 8 had rebleeding. 1 A higher proportion of patients had severe portal hypertensive gastropathy on follow up and 3 developed ectopic duodenal varices. Of all the patients who had rebleeding (n=34), about a quarter bled from gastric varices, 9% from severe portal hypertensive gastropathy and 6% from ectopic varices. What is more important is that all these rebleeding events occurred in the late follow up period indicating that such sequelae may continue to evolve through the life of the patient. Although many of these rebleeding episodes were successfully managed using repeated sessions of sclerotherapy or endoscopic cyanoacrylate injection, and only one required surgery, one cannot discount the need for continued follow up after successful variceal eradication for period extending beyond 10 years and possibly even life long! Symptomatic portal biliopathy occurred in 12 (6%) patients, of whom 4 required surgery; however, it is not known how many had biliopathy before sclerotherapy was initiated. Hence we cannot draw any inference about the natural course or progression of portal biliopathy from this study. We, as well as others have observed a high prevalence of asymptomatic biliopathy (84%) in a cohort of patients with EHPVO who were followed up prospectively before and after PLRS with serial magnetic resonance cholangiopancreatography studies. 18, 19 Symptomatic portal biliopathy is a complex problem, which may have an unpredictable response to shunt surgery, may need repeated endoscopic biliary intervention procedures and surgical drainage, and may cause serious morbidity and mortality in the short as well as long term. 20, 21 QOL issues are particularly important in patients with EHPVO, who are usually young. A rigorous schedule of endoscopic variceal obliteration, and then follow up surveillance for 10-20 years, needs repeated hospital visits, which are likely to adversely impact a young patient and his/her family in many ways. In addition, about 15% of patients undergoing repeated EST may develop esophageal strictures requiring endoscopic dilatation 1 adding to the hospital visits. It would be important to assess the overall impact of these demands on a growing child. Apart from the risk of rebleeding, these patients may have to contend with issues related to growth retardation 22 and a large and at times painful spleen with persistent hypersplenism (about 20%; primary indication for delayed surgery in 6% of cases in the study by Thomas et al. 1 Springer Lest this sounds like an unabashed promotion of shunt surgery, we would like to emphasize that level 1 evidence is not available for any of the therapeutic modalities for patients with non-cirrhotic portal hypertension. The study by Thomas et al. in this issue of the Journal is an important contribution and provides long-term data on the role of endoscopic variceal eradication, that were hitherto not available. In India, the expertise to provide effective endoscopic variceal obliteration is more widely available than that for shunt surgery. Hence, despite several advantages of surgical therapy over endoscopic variceal obliteration, endoscopy will continue to be used as an effective modality to treat active variceal bleeding, and manage patients with failure of surgery as also varices in those patients who are not eligible for shunt surgery because of non-availability of a suitable vein. For the rest of the patients with EHPVO, endoscopists will continue to play a role till the expertise for surgery is more widely available. But the knife will remain relevant for times to come.
